Oxidized low density lipoprotein enhanced RANKL expression in human osteoblast-like cells. Involvement of ERK, NFkappaB and NFAT

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1832, Issue 10, 2013, Pages 1756-1764

  Mazière, Cécile ^a,b,c   Salle, Valéry ^a,b,c   Gomila, Cathy ^a,b,c   Mazière, Jean Claude ^a,b,c  

^a AMIENS UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DE PICARDIE JULES VERNE   (France)

^c SFR CAP Santé FED 4231   (France)

Author keywords

Osteoporosis; Oxidative stress; Oxidized LDL; RANKL

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; ALPHA TOCOPHEROL; BUTHIONINE SULFOXIMINE; HYDROGEN PEROXIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; OSTEOCLAST DIFFERENTIATION FACTOR; OXIDIZED LOW DENSITY LIPOPROTEIN; REACTIVE OXYGEN METABOLITE; TRANSCRIPTION FACTOR NFAT;

ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IN VITRO STUDY; OSTEOBLAST; OSTEOCLAST; OXIDATION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN DNA BINDING; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

BSO; BUTHIONINE SULFOXIMINE; CU(2+)-OXIDIZED LOW DENSITY LIPOPROTEIN; CULDL; H(2)O(2); HYDROGEN PEROXIDE; MPO-LDL; MYELOPEROXIDASE-OXIDIZED LDL; NATIVE LDL; NFAT; NLDL; NUCLEAR FACTOR OF ACTIVATED T CELLS; OPG; OSTEOPOROSIS; OSTEOPROTEGERIN; OXIDATIVE STRESS; OXIDIZED LDL; OXLDL; RANKL; REACTIVE OXYGEN SPECIES; RECEPTOR ACTIVATOR OF NFKAPPAB LIGAND; ROS; SMC-LDL; SMOOTH MUSCLE CELL-OXIDIZED LDL;

EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; LIPOPROTEINS, LDL; NF-KAPPA B; NFATC TRANSCRIPTION FACTORS; OSTEOBLASTS; PEROXIDASE; RANK LIGAND; REACTIVE OXYGEN SPECIES;

EID: 84879557615     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2013.05.033     Document Type: Article

References (38)

1. Wong B.R., Rho J., Arron J., Robinson E., Orlinick J., Chao M., Kalachikov S., Cayani E., Bartlett F.S., Frankel W.N., Lee S.Y., Choi Y. TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J. Biol. Chem. 1997, 272:25190-25194.
2. Lacey D.L., Timms E., Tan H.L., Kelley M.J., Dunstan C.R., Burgess T., Elliott R., Colombero A., Elliott G., Scully S., Hsu H., Sullivan J., Hawkins N., Davy E., Capparelli C., Eli A., Qian Y.X., Kaufman S., Sarosi I., Shalhoub V., Senaldi G., Guo J., Delaney J., Boyle W.J. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998, 93:165-176.
3. Yasuda H., Shima N., Nakagawa N., Yamaguchi K., Kinosaki M., Mochizuki S., Tomoyasu A., Yano K., Goto M., Murakami A., Tsuda E., Morinaga T., Higashio K., Udagawa N., Takahashi N., Suda T. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:3597-3602.
4. Wong B.R., Josien R., Choi Y. TRANCE is a TNF family member that regulates dendritic cell and osteoclast function. J. Leukoc. Biol. 1999, 65:715-724.
5. Silva I., Branco J.C. Rank/Rankl/opg: literature review. Acta Rheumatol. Port. 2011, 36:209-218.
6. Bridgeman M.B., Pathak R. Denosumab for the reduction of bone loss in postmenopausal osteoporosis: a review. Clin. Ther. 2011, 33:1547-1559.
7. Tsourdi E., Rachner T.D., Rauner M., Hamann C., Hofbauer L.C. Denosumab for bone diseases: translating bone biology into targeted therapy. Eur. J. Endocrinol. 2011, 165:833-840.
8. Manolagas S.C. From estrogen-centric to aging and oxidative stress: a revised perspective of the pathogenesis of osteoporosis. Endocr. Rev. 2010, 31:266-300.
9. Maggio D., Barabani M., Pierandrei M., Polidori M.C., Catani M., Mecocci P., Senin U., Pacifici R., Cherubini A. Marked decrease in plasma antioxidants in aged osteoporotic women: results of a cross-sectional study. J. Clin. Endocrinol. Metab. 2003, 88:1523-1527.
10. Basu S., Michaëlsson K., Olofsson H., Johansson S., Melhus H. Association between oxidative stress and bone mineral density. Biochem. Biophys. Res. Commun. 2001, 288:275-279.
11. Almeida M., Han L., Martin-Millan M., Plotkin L.I., Stewart S.A., Roberson P.K., Kousteni S., O'Brien C.A., Bellido T., Parfitt A.M., Weinstein R.S., Jilka R.L., Manolagas S.C. Skeletal involution by age-associated oxidative stress and its acceleration by loss of sex steroids. J. Biol. Chem. 2007, 282:27285-27297.
12. Fraser J.H., Helfrich M.H., Wallace H.M., Ralston S.H. Hydrogen peroxide, but not superoxide, stimulates bone resorption in mouse calvariae. Bone 1996, 19:223-226.
13. Bax B.E., Alam A.S., Banerji B., Bax C.M., Bevis P.J., Stevens C.R., Moonga B.S., Blake D.R., Zaidi M. Stimulation of osteoclastic bone resorption by hydrogen peroxide. Biochem. Biophys. Res. Commun. 1992, 183:1153-1158.
14. Bai X.C., Lu D., Liu A.L., Zhang Z.M., Li X.M., Zou Z.P., Zeng W.S., Cheng B.L., Luo S.Q. Reactive oxygen species stimulates receptor activator of NF-kappaB ligand expression in osteoblast. J. Biol. Chem. 2005, 280:17497-17506.
15. Baek K.H., Oh K.W., Lee W.Y., Lee S.S., Kim M.K., Kwon H.S., Rhee E.J., Han J.H., Song K.H., Cha B.Y., Lee K.W., Kang M.I. Association of oxidative stress with postmenopausal osteoporosis and the effects of hydrogen peroxide on osteoclast formation in human bone marrow cell cultures. Calcif. Tissue Int. 2010, 87:226-235.
16. Hofbauer L.C., Brueck C.C., Shanahan C.M., Schoppet M., Dobnig H. Vascular calcification and osteoporosis-from clinical observation towards molecular understanding. Osteoporos. Int. 2007, 18:251-259.
17. Warburton D.E., Nicol C.W., Gatto S.N., Bredin S.S. Cardiovascular disease and osteoporosis: balancing risk management. Vasc. Health Risk Manag. 2007, 3:673-689.
18. Mazière C., Conte M.A., Mazière J.C. Activation of JAK2 by the oxidative stress generated with oxidized low-density lipoprotein. Free Radic. Biol. Med. 2001, 31:1334-1340.
19. Mazière C., Morlière P., Santus R., Marcheux V., Louandre C., Conte M.A., Mazière J.C. Inhibition of insulin signaling by oxidized low density lipoprotein. Protective effect of the antioxidant vitamin E. Atherosclerosis 2004, 175:23-30.
20. Mazière C., Savitsky V., Galmiche A., Gomila C., Massy Z., Mazière J.C. Oxidized low density lipoprotein inhibits phosphate signaling and phosphate-induced mineralization in osteoblasts. Involvement of oxidative stress. Biochim. Biophys. Acta 2010, 1802:1013-1019.
21. Mazière C., Louvet L., Gomila C., Kamel S., Massy Z., Mazière J.C. Oxidized low density lipoprotein decreases Rankl-induced differentiation of osteoclasts by inhibition of Rankl signalling. J. Cell. Physiol. 2009, 221:572-578.
22. Havel R.J., Eden H.A., Bragdon J.H. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J. Clin. Invest. 1955, 34:1345-1353.
23. Podrez E.A., Schmitt D., Hoff H.F., Hazen S.L. Myeloperoxidase-generated reactive nitrogen species convert LDL into an atherogenic form in vitro. J. Clin. Invest. 1999, 103:1547-1560.
24. Yagi K. Lipid peroxide and human diseases. Chem. Phys. Lipids 1947, 45:337-351.
25. Bligh E.G., Dyer W.J. A rapid method of total lipid extraction and purification. Can. J. Biochem. Physiol. 1959, 37:911-917.
26. Scott J.A., Homcy C.J., Khaw B.A., Rabito C.A. Quantitation of intracellular oxidation in a renal epithelial cell line. Free Radic. Biol. Med. 1988, 4:79-83.
27. Brodeur M.R., Brissette L., Falstrault L., Ouellet P., Moreau R. Influence of oxidized low-density lipoproteins (LDL) on the viability of osteoblastic cells. Free Radic. Biol. Med. 2008, 44:506-517.
28. Graham L.S., Parhami F., Tintut Y., Kitchen C.M., Demer L.L., Effros R.B. Oxidized lipids enhance RANKL production by T lymphocytes: implications for lipid-induced bone loss. Clin. Immunol. 2009, 133:265-275.
29. Tao H., Okamoto M., Nishikawa M., Yoshikawa H., Myoui A. P38 mitogen-activated protein kinase inhibitor, FR167653, inhibits parathyroid hormone related protein-induced osteoclastogenesis and bone resorption. PLoS One 2011, 6:e23199.
30. Tseng W., Graham L.S., Geng Y., Reddy A., Lu J., Effros R.B., Demer L., Tintut Y. PKA-induced receptor activator of NF-kappaB ligand (RANKL) expression in vascular cells mediates osteoclastogenesis but not matrix calcification. J. Biol. Chem. 2010, 285:29925-29931.
31. Lee H.L., Bae O.Y., Baek K.H., Kwon A., Hwang H.R., Qadir A.S., Park H.J., Woo K.M., Ryoo H.M., Baek J.H. High extracellular calcium-induced NFATc3 regulates the expression of receptor activator of NF-κB ligand in osteoblasts. Bone 2011, 49:242-249.
32. Geoffroy V., Kneissel M., Fournier B., Boyde A., Matthias P. High bone resorption in adult aging transgenic mice overexpressing cbfa1/runx2 in cells of the osteoblastic lineage. Mol. Cell. Biol. 2002, 22:6222-6233.
33. Roccisana J.L., Kawanabe N., Kajiya H., Koide M., Roodman G.D., Reddy S.V. Functional role for heat shock factors in the transcriptional regulation of human RANK ligand gene expression in stromal/osteoblast cells. J. Biol. Chem. 2004, 279:10500-10507.
34. Fu Q., Jilka R.L., Manolagas S.C., O'Brien C.A. Parathyroid hormone stimulates receptor activator of NFkappa B ligand and inhibits osteoprotegerin expression via protein kinase A activation of cAMP-response element-binding protein. J. Biol. Chem. 2002, 277:48868-48875.
35. Hashizume M., Hayakawa N., Mihara M. IL-6 trans-signalling directly induces RANKL on fibroblast-like synovial cells and is involved in RANKL induction by TNF-alpha and IL-17. Rheumatology (Oxford) 2008, 47:1635-1640.
36. Jain J., McCaffrey P.G., Miner Z., Kerppola T.K., Lambert J.N., Verdine G.L., Curran T., Rao A. The T-cell transcription factor NFATp is a substrate for calcineurin and interacts with Fos and Jun. Nature 1993, 365:352-355.
37. Mazière C., Morlière P., Massy Z., Kamel S., Louandre C., Conte M.A., Mazière J.C. Oxidized low-density lipoprotein elicits an intracellular calcium rise and increases the binding activity of the transcription factor NFAT. Free Radic. Biol. Med. 2005, 38:472-480.
38. Tintut Y., Morony S., Demer L.L. Hyperlipidemia promotes osteoclastic potential of bone marrow cells ex vivo. Arterioscler. Thromb. Vasc. Biol. 2004, 24:6-10.